278 related articles for article (PubMed ID: 15327418)
1. Idiopathic membranous nephropathy: definition and relevance of a partial remission.
Troyanov S; Wall CA; Miller JA; Scholey JW; Cattran DC;
Kidney Int; 2004 Sep; 66(3):1199-205. PubMed ID: 15327418
[TBL] [Abstract][Full Text] [Related]
2. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.
Troyanov S; Wall CA; Miller JA; Scholey JW; Cattran DC;
J Am Soc Nephrol; 2005 Apr; 16(4):1061-8. PubMed ID: 15716334
[TBL] [Abstract][Full Text] [Related]
3. Out of Africa: Complete and partial remissions as a combined outcome in patients with idiopathic membranous glomerulonephritis in Cape Town.
Ameh OI; Swanepoel CR; Aderibigbe A; Kengne AP; Okpechi IG
Nephrology (Carlton); 2016 Dec; 21(12):1010-1016. PubMed ID: 26706191
[TBL] [Abstract][Full Text] [Related]
4. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
Dumoulin A; Hill GS; Montseny JJ; Meyrier A
Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
[TBL] [Abstract][Full Text] [Related]
5. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy.
McQuarrie EP; Stirling CM; Geddes CC
Nephrol Dial Transplant; 2012 Jan; 27(1):235-42. PubMed ID: 21558430
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A treatment for idiopathic membranous nephropathy.
Yao X; Chen H; Wang Q; Tang Z; Hu W; Yin G; Liu Z; Li L
Chin Med J (Engl); 2001 Dec; 114(12):1305-8. PubMed ID: 11793859
[TBL] [Abstract][Full Text] [Related]
7. The impact of sex in primary glomerulonephritis.
Cattran DC; Reich HN; Beanlands HJ; Miller JA; Scholey JW; Troyanov S;
Nephrol Dial Transplant; 2008 Jul; 23(7):2247-53. PubMed ID: 18182409
[TBL] [Abstract][Full Text] [Related]
8. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy.
Torres A; Domínguez-Gil B; Carreño A; Hernández E; Morales E; Segura J; González E; Praga M
Kidney Int; 2002 Jan; 61(1):219-27. PubMed ID: 11786104
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
du Buf-Vereijken PW; Branten AJ; Wetzels JF;
Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
[TBL] [Abstract][Full Text] [Related]
10. Clinical Predictors of Response to Prednisone Plus Cyclophosphamide in Patients with Idiopathic Membranous Nephropathy.
Li S; Wang L; Zhang M; Zhou W; Fang W; Wang Q; Qi C; Mou S; Shao X; Ni Z
Nephron; 2017; 135(2):87-96. PubMed ID: 27974710
[TBL] [Abstract][Full Text] [Related]
11. Membranous Nephropathy: Quantifying Remission Duration on Outcome.
Cattran DC; Kim ED; Reich H; Hladunewich M; Kim SJ;
J Am Soc Nephrol; 2017 Mar; 28(3):995-1003. PubMed ID: 27756808
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.
Cattran DC; Appel GB; Hebert LA; Hunsicker LG; Pohl MA; Hoy WE; Maxwell DR; Kunis CL;
Kidney Int; 2001 Apr; 59(4):1484-90. PubMed ID: 11260412
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
14. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.
Alexopoulos E; Papagianni A; Tsamelashvili M; Leontsini M; Memmos D
Nephrol Dial Transplant; 2006 Nov; 21(11):3127-32. PubMed ID: 16968719
[TBL] [Abstract][Full Text] [Related]
15. Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.
Thompson A; Cattran DC; Blank M; Nachman PH
J Am Soc Nephrol; 2015 Dec; 26(12):2930-7. PubMed ID: 26078365
[TBL] [Abstract][Full Text] [Related]
16. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
Hofstra JM; Branten AJ; Wirtz JJ; Noordzij TC; du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus.
Caro J; Gutiérrez-Solís E; Rojas-Rivera J; Agraz I; Ramos N; Rabasco C; Espinosa M; Valera A; Martín M; Frutos MÁ; Perea L; Juárez GF; Ocaña J; Arroyo D; Goicoechea M; Fernández L; Oliet A; Hernández Y; Romera A; Segarra A; Praga M;
Nephrol Dial Transplant; 2015 Mar; 30(3):467-74. PubMed ID: 25274748
[TBL] [Abstract][Full Text] [Related]
18. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
Goumenos DS; Ahuja M; Davlouros P; El Nahas AM; Brown CB
Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
[TBL] [Abstract][Full Text] [Related]
19. The natural history of the non-nephrotic membranous nephropathy patient.
Hladunewich MA; Troyanov S; Calafati J; Cattran DC;
Clin J Am Soc Nephrol; 2009 Sep; 4(9):1417-22. PubMed ID: 19661220
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria.
Passerini P; Pasquali S; Cesana B; Zucchelli P; Ponticelli C
Nephrol Dial Transplant; 1989; 4(6):525-9. PubMed ID: 2507973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
